View Older Stories View More Recent Stories

Mar 31, 2025 07:00AM BioLineRx Reports 2024 Financial Results and Provides Corporate Update
Mar 24, 2025 07:00AM BioLineRx to Report 2024 Annual Results on March 31, 2025
Jan 21, 2025 07:01AM BioLineRx (BLRX) Issues Letter to Shareholders
Jan 21, 2025 07:00AM BioLineRx Issues Letter to Shareholders
Jan 17, 2025 07:00AM BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares
Nov 25, 2024 07:00AM BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
Nov 21, 2024 06:31AM BioLineRx (BLRX) and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA
Nov 21, 2024 06:30AM BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
Nov 20, 2024 07:19AM BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Nov 5, 2024 09:00AM BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
Oct 16, 2024 07:02AM BioLineRx (BLRX) Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
Oct 16, 2024 07:00AM BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
Sep 17, 2024 01:01PM BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
Aug 15, 2024 07:00AM BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
Aug 8, 2024 07:00AM BioLineRx to Report Second Quarter 2024 Results on August 15, 2024
May 30, 2024 07:00AM BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applicatio
May 28, 2024 07:00AM BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates
May 24, 2024 07:00AM BioLineRx (BLRX) Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial of Motixafortide
May 24, 2024 07:00AM BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO)
May 22, 2024 07:00AM BioLineRx to Report First Quarter 2024 Results on May 28, 2024
May 17, 2024 05:00PM BioLineRx (BLRX) Receives Nasdaq Non-compliance Notice
May 17, 2024 05:00PM BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
May 6, 2024 07:00AM BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024
Apr 17, 2024 07:00AM BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting
Apr 10, 2024 07:06AM BioLineRx (BLRX) Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
Apr 10, 2024 07:00AM BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement
Apr 1, 2024 09:01AM BioLineRx (BLRX) Announces 7.5M Share Offering at $0.80/sh
Apr 1, 2024 09:00AM BioLineRx Announces $6 Million Registered Direct Offering
Mar 26, 2024 07:00AM BioLineRx Reports 2023 Financial Results and Recent Corporate and Portfolio Updates
Mar 20, 2024 07:00AM BioLineRx to Report 2023 Annual Financial Results on March 26, 2024
Mar 6, 2024 08:00AM Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Mar 4, 2024 07:03AM BioLineRx (BLRX) Receives Patent for Method of Manufacturing Motixafortide
Mar 4, 2024 07:00AM BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (BL-8040) Suitable for Large Scale Production
Feb 28, 2024 07:00AM BioLineRx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC)
Feb 16, 2024 07:00AM BioLineRx Announces Acceptance of Two Poster Presentations on APHEXDA® (motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetin
Dec 21, 2023 07:00AM BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease
Nov 20, 2023 07:00AM BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Nov 13, 2023 07:00AM BioLineRx to Report Third Quarter 2023 Results on November 20, 2023
Oct 12, 2023 07:00AM BioLineRx Announces Closing of Exclusive License Agreement to Motixafortide in Asia and Concurrent Strategic Equity Investment
Sep 28, 2023 07:01AM BioLineRx (BLRX) Reports Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide
Sep 28, 2023 07:00AM BioLineRx Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (PDAC)
Sep 19, 2023 07:00AM BioLineRx Announces Acceptance of Oral Presentation on Pilot Phase Data from Phase 2 Combination Clinical Trial with Motixafortide in First-Line PDAC at AACR Special Conference on Pancreatic Cancer
Sep 11, 2023 07:00AM BioLineRx (BLRX) Announces FDA Approval of APHEXDA in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with
Sep 11, 2023 07:00AM BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in P
Aug 30, 2023 07:00AM BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates
Aug 22, 2023 07:00AM BioLineRx to Report Second Quarter 2023 Results on August 30, 2023
Jul 17, 2023 07:00AM BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase; Combination Trial Includes Investi
Nov 23, 2020 07:00AM BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Nov 18, 2020 07:05AM BioLineRx (BLRX) Begins Phase 1b Clinical Trial in Patients with ARDS Secondary to COVID-19 & Other Respiratory Viral Infections
Nov 18, 2020 07:00AM BioLineRx to Report Third Quarter 2020 Results on November 23, 2020
View More Recent Stories View Older Stories